Organization: Health Canada
Year: 2024
Month: June
Request Number: A-2023-001220
Request Summary: Correspondence relating to any abbreviated new drug submission (ANDS) filed since July 1, 2023 where the medicinal ingredient is liraglutide alone and the indication includes the treatment of adults with type 2 diabetes.
Disposition: Disclosed in part
Number of pages: 5